Industry
Biotechnology
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Loading...
Open
1.48
Mkt cap
96M
Volume
287K
High
1.50
P/E Ratio
-1.23
52-wk high
3.79
Low
1.44
Div yield
N/A
52-wk low
1.08
Portfolio Pulse from Avi Kapoor
June 25, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 10:48 am
Portfolio Pulse from Dylan Berman
June 24, 2024 | 3:32 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 3:17 pm
Portfolio Pulse from ryanfaloona@benzinga.com
June 24, 2024 | 12:39 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:58 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 11:11 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.